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BACKGROUND
In phase 2 trials, treatment with the combination of the nucleotide polymerase 
inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of 
sustained virologic response in patients chronically infected with hepatitis C virus 
(HCV) genotype 2 or 3.
METHODS
We conducted two randomized, phase 3, open-label studies involving patients who 
had received previous treatment for HCV genotype 2 or 3 and those who had not 
received such treatment, including patients with compensated cirrhosis. In one 
trial, patients with HCV genotype 2 were randomly assigned in a 1:1 ratio to receive 
sofosbuvir–velpatasvir, in a once-daily, fixed-dose combination tablet (134 pa-
tients), or sofosbuvir plus weight-based ribavirin (132 patients) for 12 weeks. In a 
second trial, patients with HCV genotype 3 were randomly assigned in a 1:1 ratio 
to receive sofosbuvir–velpatasvir for 12 weeks (277 patients) or sofosbuvir–ribavirin 
for 24 weeks (275 patients). The primary end point for the two trials was a sus-
tained virologic response at 12 weeks after the end of therapy.
RESULTS
Among patients with HCV genotype 2, the rate of sustained virologic response in 
the sofosbuvir–velpatasvir group was 99% (95% confidence interval [CI], 96 to 100), 
which was superior to the rate of 94% (95% CI, 88 to 97) in the sofosbuvir–riba-
virin group (P = 0.02). Among patients with HCV genotype 3, the rate of sustained 
virologic response in the sofosbuvir–velpatasvir group was 95% (95% CI, 92 to 98), 
which was superior to the rate of 80% (95% CI, 75 to 85) in the sofosbuvir–ribavirin 
group (P<0.001). The most common adverse events in the two studies were fatigue, 
headache, nausea, and insomnia.
CONCLUSIONS
Among patients with HCV genotype 2 or 3 with or without previous treatment, 
including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir–
velpatasvir resulted in rates of sustained virologic response that were superior 
to those with standard treatment with sofosbuvir–ribavirin. (Funded by Gilead 
Sciences; ASTRAL-2 ClinicalTrials.gov number, NCT02220998; and ASTRAL-3, 
NCT02201953.)
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Hepatitis C virus (HCV) genotypes 2 and 3 account for an estimated 35% of global HCV infections, affecting up to 
58 million persons.1,2 Unlike HCV genotype 1, 
genotypes 2 and 3 are common in low-income 
regions in Asia, sub-Saharan Africa, Latin Amer-
ica, and Eastern Europe.1 Before the advent of 
direct-acting antiviral agents, HCV genotypes 2 
and 3 were grouped together in treatment guide-
lines as “easy-to-treat” genotypes. However, re-
cent studies have shown that HCV genotype 3 is 
associated with more rapid disease progression 
and lower rates of response to treatment than is 
HCV genotype 2, especially in patients with cir-
rhosis and those who have not had a response to 
previous treatment.3,4 The current standard treat-
ment is 12 to 20 weeks of sofosbuvir–ribavirin 
for patients with HCV genotype 2 and 24 weeks 
of sofosbuvir–ribavirin for patients with HCV 
genotype 3.5,6 The inclusion of ribavirin, which 
has known hematologic and other toxic effects, 
as well as teratogenic effects, limits the use of 
this regimen, particularly among patients of 
childbearing age, those with heart disease, and 
those who live in regions where hemoglobin-
opathies are highly prevalent.7 A simple, ribavirin-
free regimen that would be effective across HCV 
genotypes might allow clinicians to dispense 
with pretreatment genotype testing and on-
treatment monitoring, which would potentially 
allow for the expansion of access to treatment in 
low- and middle-income regions.
Sofosbuvir is a nucleotide analogue NS5B poly-
merase inhibitor that is approved for the treat-
ment of HCV genotypes 2 and 3 in combination 
with ribavirin.8 Velpatasvir (formerly GS-5816, 
Gilead Sciences) is a new NS5A inhibitor with 
antiviral activity against all HCV genotypes.9-11 
In phase 2 trials, 12 weeks of treatment with the 
combination of sofosbuvir and velpatasvir result-
ed in high rates of sustained virologic response 
in patients with HCV genotype 2 or 3.12,13
Here, we present the results of two random-
ized, controlled, phase 3 trials (ASTRAL-2 and 
ASTRAL-3) in which treatment with a fixed-
dose combination tablet of sofosbuvir and vel-
patasvir for 12 weeks was compared with stan-
dard treatment with sofosbuvir plus ribavirin 
for 12 or 24 weeks in patients who had received 
prior treatment for HCV genotype 2 or 3 infec-
tion and in those who had not received such 
treatment, including those with compensated 
cirrhosis.
Me thods
Patients
Eligibility criteria for the two trials were identi-
cal, except that the ASTRAL-2 trial enrolled pa-
tients with HCV genotype 2 and the ASTRAL-3 
trial enrolled patients with HCV genotype 3. Eli-
gible patients were 18 years of age or older and 
had at least a 6-month history of HCV infection. 
The two protocols specified that patients who 
did not have a sustained virologic response after 
previous treatment with an interferon-containing 
regimen could account for approximately 20% of 
the study population, although patients who dis-
continued previous therapy because of an adverse 
event were not eligible. The two studies had an 
intended enrollment of patients with compen-
sated cirrhosis of approximately 20%, with the 
presence of compensated cirrhosis determined 
on liver biopsy showing cirrhosis (Metavir stage 4 
or Ishak score of 5 or 6), a FibroTest score of 
more than 0.75 and a ratio of aspartate amino-
transferase to platelets of more than 2, or a 
FibroScan result of more than 12.5 kPa. Patients 
with clinical evidence of hepatic decompensation 
(i.e., ascites, encephalopathy, or variceal hemor-
rhage) were excluded. There were no upper limits 
on age or body-mass index. All patients provided 
written informed consent. Full eligibility criteria 
are provided in the study protocol, available with 
the full text of this article at NEJM.org.
Study Oversight
The two studies were approved by the institu-
tional review board or independent ethics com-
mittee at each participating site and were con-
ducted in compliance with the Declaration of 
Helsinki, Good Clinical Practice guidelines, and 
local regulatory requirements. The studies were 
designed and conducted by the sponsor (Gilead 
Sciences) in collaboration with the principal in-
vestigators, according to the protocol. The spon-
sor collected the data, monitored study conduct, 
and performed the statistical analyses. Indepen-
dent data and safety monitoring committees 
reviewed the progress of the studies. The inves-
tigators, participating institutions, and sponsor 
agreed to maintain confidentiality of the data. 
All the authors had access to the data and as-
sumed responsibility for the integrity and com-
pleteness of the reported data. The initial draft 
of the manuscript was prepared by a writer em-
ployed by Gilead Sciences and the primary inves-
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tigators with input from all the authors. The 
studies were conducted and reported with fidel-
ity to the study protocol.
Study Designs
In the two multicenter trials, patients with 
chronic HCV infection were randomly assigned 
in a 1:1 ratio to receive a fixed-dose combina-
tion tablet containing 400 mg of sofosbuvir and 
100 mg of velpatasvir once daily for 12 weeks 
or 400 mg of sofosbuvir plus ribavirin (RibaSphere, 
Kadmon) for 12 weeks (for patients with HCV 
genotype 2) or 24 weeks (for patients with HCV 
genotype 3). Ribavirin was administered orally 
twice daily, with doses determined according to 
body weight (1000 mg daily in patients with a 
body weight of <75 kg and 1200 mg daily in 
patients with a body weight of ≥75 kg). All in-
vestigators, patients, and trial personnel were 
aware of the treatment assignments at all points 
in the two trials.
In ASTRAL-2, patients were enrolled at 51 sites 
in the United States from October 15, 2014, 
through December 18, 2014. In ASTRAL-3, pa-
tients were enrolled at 76 sites in the United 
States, Canada, Europe (France, Germany, Italy, 
and the United Kingdom), Australia, and New 
Zealand from July 30, 2014, through December 
17, 2014. In the two studies, randomization was 
stratified according to the presence or absence 
of cirrhosis at screening and status regarding 
previous treatment.
Study Assessments
For the two trials, screening assessments includ-
ed measurement of serum HCV RNA levels and 
IL28B genotyping in addition to standard labora-
tory and clinical testing. Serum HCV RNA was 
measured with the use of the COBAS AmpliPrep/
COBAS TaqMan HCV Quantitative Test, version 
2.0 (Roche Molecular Systems), with a lower 
limit of quantification of 15 IU per milliliter. 
The HCV genotype and subtype were determined 
with the use of the VERSANT HCV Genotype 2.0 
Assay (Siemens). For patients for whom geno-
typing data could not be provided with the 
VERSANT assay, the TRUGENE HCV 5′NC 
 Genotyping Kit was used. If genotyping with the 
TRUGENE test was unsuccessful, NS5B sequenc-
ing was performed. IL28B genotyping was per-
formed by means of polymerase-chain-reaction 
amplification and sequencing of the rs12979860 
single-nucleotide polymorphism.
On-treatment assessments included standard 
laboratory testing, along with measurement of 
serum HCV RNA levels, recording of vital signs, 
electrocardiography, and symptom-directed phys-
ical examinations. All adverse events were re-
corded and graded according to a standardized 
scale. (Details are provided in the study protocol.)
Deep sequencing of the HCV NS5A and NS5B 
coding regions was performed on samples ob-
tained from all patients at baseline and again for 
all patients with virologic failure. Sequences that 
were obtained at the time of virologic failure 
were compared with sequences from baseline 
samples to detect resistance-associated variants 
that emerged during treatment. We report resis-
tance-associated variants that were present in 
more than 1% of the sequence reads.
Primary End Point
The primary efficacy end point for the two trials 
was a sustained virologic response, which was 
defined as an HCV RNA level of less than 15 IU 
per milliliter at 12 weeks after the end of treat-
ment. All patients who underwent randomiza-
tion and received at least one dose of a study 
drug were included in the analysis of the pri-
mary end point.
Statistical Analysis
We used the same statistical methods in the two 
studies. Efficacy and safety were assessed in all 
patients who underwent randomization and re-
ceived at least one dose of a study drug.
In the two studies, the primary efficacy hy-
pothesis was that the rate of sustained virologic 
response among patients receiving sofosbuvir–
velpatasvir would be noninferior to that among 
patients receiving sofosbuvir–ribavirin, with a 
noninferiority margin of 10 percentage points. If 
the lower boundary of the 95% confidence inter-
val for the strata-adjusted between-group differ-
ence in proportions was more than −10%, a two-
sided stratified Cochran–Mantel–Haenszel test 
would be used to test for the superiority of 
sofosbuvir–velpatasvir over sofosbuvir–ribavirin 
at a significance level of 0.05.
For ASTRAL-2, we determined that enroll-
ment of 120 patients in each treatment group 
would provide a power of 90% to establish non-
inferiority between the two groups on the basis 
of a rate of sustained virologic response of 94%, 
with the use of a one-sided test at a significance 
level of 0.025. For ASTRAL-3, we determined 
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that enrollment of 250 patients in each treatment 
group would provide a power of 94% to establish 
noninferiority between the two groups on the 
basis of a rate of sustained virologic response of 
89%, with the use of a one-sided test at a signifi-
cance level of 0.025. Point estimates and two-
sided 95% exact confidence intervals that are 
based on the Clopper–Pearson method are pro-
vided for rates of sustained virologic response 
for all treatment groups, as well as selected sub-
groups.
R esult s
Characteristics of the Patients
A total of 317 patients with HCV genotype 2 
were initially screened for the ASTRAL-2 trial. 
Of these patients, 269 underwent randomization, 
and 266 began treatment (Table S1 and Fig. S1 
in the Supplementary Appendix, available at 
NEJM.org). Most of the patients were white men 
and had a non-CC IL28B genotype (Table 1). (The 
non-CC genotype has been associated with a 
reduced response to HCV treatment.) A total of 
14% of the patients had cirrhosis, and 14 to 15% 
had received unsuccessful treatment for HCV.
A total of 652 patients with HCV genotype 3 
were initially screened for the ASTRAL-3 trial. 
Of these patients, 558 underwent randomization 
and 552 began treatment (Table S2 and Fig. S2 
in the Supplementary Appendix). As in the 
 ASTRAL-2 trial, most of the patients were white 
men with a non-CC IL28B genotype. However, 
a larger percentage of patients than in the 
 ASTRAL-2 trial had cirrhosis (29 to 30%) and 
had undergone unsuccessful treatment (26%).
Efficacy
ASTRAL-2 Trial
Among patients with HCV genotype 2, the rate 
of sustained virologic response at 12 weeks after 
treatment was 99% (95% confidence interval 
[CI], 96 to 100) among those who had received 
sofosbuvir–velpatasvir for 12 weeks, as compared 
with 94% (95% CI, 88 to 97) among those who 
had received sofosbuvir–ribavirin for 12 weeks 
(Table 2). Thus, the group of patients who had 
received sofosbuvir–velpatasvir met the primary 
end point with a rate of sustained virologic re-
sponse that was significantly superior to that 
among patients who had received the standard 
treatment of sofosbuvir–ribavirin for 12 weeks, 
with a strata-adjusted absolute difference of 5.2 
percentage points (95% CI, 0.2 to 10.3; P = 0.02 
with the Cochran–Mantel–Haenszel test strati-
fied according to cirrhosis status and previous 
treatment).
There were no virologic failures among 
 patients receiving sofosbuvir–velpatasvir. One 
57-year-old black man discontinued study treat-
ment on day 1 after receiving one dose of the 
study drug because of adverse events (as de-
scribed in the Safety section). Of the 132 patients 
who received sofosbuvir–ribavirin, 6 (5%) had a 
virologic relapse after the end of treatment, and 
2 other patients were lost to follow-up.
ASTRAL-3 Trial
Among patients with HCV genotype 3, the rate 
of sustained virologic response at 12 weeks after 
treatment was 95% (95% CI, 92 to 98) among 
those who had received sofosbuvir–velpatasvir 
for 12 weeks, as compared with 80% (95% CI, 75 
to 85) among those who had received 24 weeks 
of sofosbuvir–ribavirin (Table 2). The sustained 
virologic response rate with 12 weeks of sofos-
buvir–velpatasvir was significantly superior to 
that with 24 weeks of sofosbuvir–ribavirin. The 
strata-adjusted absolute difference was 14.8 per-
centage points (95% CI, 9.6 to 20.0; P<0.001 
with the Cochran–Mantel–Haenszel test strati-
fied according to cirrhosis status and previous 
treatment).
Among the 277 patients who received sofos-
buvir–velpatasvir, 11 (4%) had virologic failure 
after the end of treatment, and 2 patients were 
lost to follow-up. Characteristics of the 11 pa-
tients in the sofosbuvir–velpatasvir group who 
had a relapse are provided in Table S4 in the 
Supplementary Appendix. Among the 275 pa-
tients who received sofosbuvir–ribavirin, 38 (14%) 
had a relapse after treatment, 1 had virologic 
failure during treatment, 6 were lost to follow-
up, 4 discontinued treatment because of adverse 
events, 2 withdrew consent, 2 died, and 1 discon-
tinued treatment before achieving undetectable 
HCV RNA.
The rates of sustained virologic response in 
various patient subgroups are shown in Table S3 
in the Supplementary Appendix. Among patients 
who received sofosbuvir–velpatasvir, the rate of 
sustained virologic response was 91% among 
those with cirrhosis, as compared with 97% 
among those without cirrhosis. Among patients 
who received sofosbuvir–ribavirin, the rates of 
sustained virologic response among patients with 
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and those without cirrhosis were 66% and 87%, 
respectively. A similar pattern of response was 
seen according to whether patients had received 
previous treatment. Among patients in the so-
fosbuvir–velpatasvir group, the rate of sustained 
virologic response was 90% among those who 
had received previous HCV treatment, as com-
pared with 97% among those who had received 
no previous treatment. The corresponding rates 
among patients in the sofosbuvir–ribavirin group 
were 63% and 86%. The rate of sustained viro-
logic response among patients who had received 
previous treatment and who had evidence of cir-
rhosis was 89% in the sofosbuvir–velpatasvir 
group as compared with 58% in the sofosbuvir–
ribavirin group (Fig. 1). Sustained virologic re-
sponse did not appear to be correlated with the 
IL28B genotype or early viral kinetics.
Viral Resistance Testing
In the ASTRAL-2 trial, deep sequencing indicated 
that approximately 60% of the 134 patients in the 
sofosbuvir–velpatasvir group had NS5A resistance-
associated variants and 10% had NS5B resis-
tance-associated variants at baseline. The most 
prevalent NS5A variant observed at baseline was 
L31M in 52% of the patients. Despite the pres-
ence of pretreatment NS5A and NS5B resistance-
Characteristic HCV Genotype 2 HCV Genotype 3
Sofosbuvir–Velpatasvir 
for 12 Wk 
(N = 134)
Sofosbuvir–Ribavirin 
for 12 Wk 
(N = 132)
Sofosbuvir–Velpatasvir 
for 12 Wk 
(N = 277)
Sofosbuvir–Ribavirin 
for 24 Wk 
(N = 275)
Mean age (range) — yr 57 (26–81) 57 (23–76) 49 (21–76) 50 (19–74)
Male sex — no. (%) 86 (64) 72 (55) 170 (61) 174 (63)
Mean body-mass index (range)† 28 (17–45) 29 (19–61) 26 (17–48) 27 (17–56)
Race — no. (%)‡
White 124 (93) 111 (84) 250 (90) 239 (87)
Black  6 (4) 12 (9)  3 (1)   1 (<1)
Asian  1 (1)  5 (4) 23 (8)  29 (11)
Other  3 (2)  4 (3)   1 (<1)  6 (2)
HCV RNA
Mean — log10 IU/ml 6.5±0.78 6.4±0.74 6.2±0.72 6.3±0.71
≥800,000 IU/ml — no. (%) 111 (83) 101 (77) 191 (69) 194 (71)
IL28B genotype — no. (%)
CC 55 (41)  46 (35) 105 (38) 111 (40)
CT 61 (46)  64 (48) 148 (53) 133 (48)
TT 18 (13)  22 (17) 24 (9)  31 (11)
Compensated cirrhosis — no. (%) 19 (14)  19 (14)  80 (29)  83 (30)
Previous HCV treatment — no. (%)
No 115 (86) 112 (85) 206 (74) 204 (74)
Yes 19 (14)  20 (15)  71 (26)  71 (26)
Response to previous HCV treat-
ment — no./total no. (%)
No response 3/19 (16) 3/20 (15) 20/71 (28) 24/71 (34)
Relapse or breakthrough 16/19 (84) 17/20 (85) 51/71 (72) 47/71 (66)
*  Plus–minus values are means ±SD. Patients with hepatitis C virus (HCV) genotype 2 were evaluated in the ASTRAL-2 trial, and those with 
genotype 3 in the ASTRAL-3 trial. There were no significant differences between the two groups.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race was self-reported.
Table 1. Characteristics of the Patients at Baseline.*
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associated variants in the ASTRAL-2 trial, no 
patient receiving sofosbuvir–velpatasvir had viro-
logic failure.
In the ASTRAL-3 trial, of the 274 patients in 
the sofosbuvir–velpatasvir group who had avail-
able data on virologic outcome (sustained viro-
logic response or virologic failure) with deep 
sequencing data, 43 (16%) had detectable NS5A 
resistance-associated variants (A30K, L31M, and 
Y93H) at baseline. Of these patients, 38 (88%) 
had a sustained virologic response. Of the 25 pa-
tients with the Y93H variant at baseline, 21 (84%) 
had a sustained virologic response. Of the 231 
patients without NS5A resistance-associated vari-
ants at baseline, 225 (97%) had a sustained viro-
logic response. All 10 patients with baseline NS5B 
resistance-associated variants (N142T, L159F, 
E237G, L320I, and V321A/I) had a sustained 
virologic response (Fig. S3 in the Supplementary 
Appendix).
Safety
In the two trials, 1 patient receiving sofosbuvir–
velpatasvir discontinued all treatment prema-
turely because of an adverse event. This patient, 
a 57-year-old black man in the sofosbuvir–velpa-
tasvir group in the ASTRAL-2 trial, discontinued 
on day 1 of treatment because of anxiety, head-
ache, and difficulty concentrating. A total of 9 of 
275 patients (3%) in the sofosbuvir–ribavirin 
group in the ASTRAL-3 trial discontinued riba-
virin because of adverse events (Table 3).
Serious adverse events were reported in 4 pa-
tients in the ASTRAL-2 trial, including 2 in the 
Response HCV Genotype 2 HCV Genotype 3
Sofosbuvir–Velpatasvir 
for 12 Wk 
(N = 134)
Sofosbuvir–Ribavirin 
for 12 Wk 
(N = 132)
Sofosbuvir–Velpatasvir 
for 12 Wk 
(N = 277)
Sofosbuvir–Ribavirin 
for 24 Wk 
(N = 275)
HCV RNA <15 IU/ml — no. (%)
During treatment period
At 2 wk 76 (57) 79 (60) 171 (62) 137 (50)
At 4 wk 120 (90) 119 (90) 253 (91) 240 (87)
After end of treatment
At 4 wk 133 (99) 127 (96) 268 (97) 225 (82)
At 12 wk* 133 (99) 124 (94) 264 (95) 221 (80)
95% CI at 12 wk 96–100  88–97  92–98  75–85
Virologic failure — no./total no. (%)
On-treatment failure 0 0 0 1/275 (<1)
Relapse 0 6/132 (5) 11/276 (4) 38/272 (14)
*  The primary efficacy end point was a sustained virologic response (HCV RNA level of <15 IU per milliliter) at 12 weeks after the end of treatment.
Table 2. Response during and after Treatment.
Figure 1. Sustained Virologic Response among Patients with HCV Genotype 3, 
According to Cirrhosis Status and Previous Treatment.
Shown are the rates of sustained virologic response at 12 weeks after treat-
ment among patients with HCV genotype 3 who were treated with sofosbuvir–
velpatasvir or sofosbuvir–ribavirin in the ASTRAL-3 study. Data for five pa-
tients in the sofosbuvir–ribavirin group for whom cirrhosis status was not 
available are not included in the analysis. The I bars represent 95% confi-
dence intervals.
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sofosbuvir–velpatasvir group (pneumonia in 1 pa-
tient and enteritis and abdominal pain in 1 patient) 
and 2 in the sofosbuvir–ribavirin group (arthral-
gia in 1 patient and depression in 1 patient) 
(Table 3, and Table S5 in the Supplementary 
Appendix). In the ASTRAL-3 trial, serious ad-
verse events were reported in 6 patients (2%) 
receiving sofosbuvir–velpatasvir and in 15 pa-
tients (5%) receiving sofosbuvir–ribavirin (Ta-
ble 3, and Table S6 in the Supplementary Appen-
dix). Across the two trials, the only serious 
adverse event that occurred in more than 1 patient 
was depression in 2 patients receiving sofosbuvir–
ribavirin (1 in each study).
In the ASTRAL-2 trial, 2 patients receiving 
sofosbuvir–velpatasvir died during the post-treat-
ment follow-up: a 56-year-old white woman died 
of cardiac arrest 131 days after the end of treat-
ment, and a 58-year-old white man died of com-
plications related to metastatic lung cancer 112 
days after the end of treatment. In the ASTRAL-3 
trial, 3 patients receiving sofosbuvir–ribavirin 
Variable HCV Genotype 2 HCV Genotype 3
Sofosbuvir–Velpatasvir 
for 12 Wk 
(N = 134)
Sofosbuvir–Ribavirin 
for 12 Wk 
(N = 132)
Sofosbuvir–Velpatasvir 
for 12 Wk 
(N = 277)
Sofosbuvir–Ribavirin 
for 24 Wk 
(N = 275)
number (percent)
Patients discontinuing treatment because 
of adverse event
1 (1) 0 0 9 (3)
Patients with event up to 30 days after last dose
Any adverse event 92 (69) 101 (77) 245 (88) 260 (95)
Serious adverse event 2 (1) 2 (2) 6 (2) 15 (5)
Death 2 (1) 0 0 3 (1)
Common adverse events*
Fatigue 20 (15) 47 (36) 71 (26) 105 (38)
Headache 24 (18) 29 (22) 90 (32) 89 (32)
Nausea 14 (10) 19 (14) 46 (17) 58 (21)
Insomnia 6 (4) 18 (14) 31 (11) 74 (27)
Irritability 4 (3) 9 (7) 23 (8) 40 (15)
Pruritus 6 (4) 7 (5) 8 (3) 35 (13)
Nasopharyngitis 8 (6) 2 (2) 34 (12) 33 (12)
Cough 4 (3) 6 (5) 14 (5) 35 (13)
Dyspepsia 1 (1) 5 (4) 9 (3) 30 (11)
Selected laboratory abnormalities
Hemoglobin concentration <10 g/dl 0 6 (5) 0 10 (4)
Lymphocyte count
350 to <500 per mm3 0 1 (1) 2 (1) 3 (1)
<500 per mm3 0 0 1 (<1) 1 (<1)
Platelet count 25,000 to <50,000 per mm3 0 0 1 (<1) 1 (<1)
Total bilirubin
>2.5 to 3.0 mg/dl 0 3 (2) 0 2 (1)
>3.0 mg/dl 0 0 0 1 (<1)
*  Adverse events were considered to be common if they occurred in at least 10% of patients in any group. To convert the values for bilirubin 
to micromoles per liter, multiply by 17.1.
Table 3. Discontinuations, Adverse Events, and Selected Laboratory Abnormalities.
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died, 2 during treatment (1 from unknown 
causes and 1 from gunshot wounds) and 1 dur-
ing follow-up (from unknown causes).
In the two trials, the rates of adverse events 
were lower among patients receiving sofosbuvir–
velpatasvir than among those receiving sofosbu-
vir–ribavirin (Table 3). Overall, the most com-
mon events in the two treatment groups were 
fatigue, headache, and nausea. Patients receiving 
24 weeks of sofosbuvir–ribavirin in the ASTRAL-3 
trial had increased rates of insomnia, irritability, 
and cough, all of which are known to be associ-
ated with ribavirin treatment.
Among patients receiving sofosbuvir–ribavi-
rin, 6 (5%) in the ASTRAL-2 trial and 10 (4%) in 
the ASTRAL-3 trial had decreased hemoglobin 
values (<10 g per deciliter); no patients receiving 
sofosbuvir–velpatasvir in either study had hemo-
globin values of less than 10 g per deciliter 
(Table 3). Grade 3 or 4 hyperbilirubinemia, a 
known side effect of ribavirin-associated hemo-
lysis, was seen in 6 patients receiving sofosbu-
vir–ribavirin in the two studies. No grade 3 or 4 
elevations in bilirubin were observed among 
patients receiving sofosbuvir–velpatasvir.
Discussion
In these multicenter, randomized, phase 3 trials, 
rates of sustained virologic response among pa-
tients with HCV genotype 2 or 3 who received 12 
weeks of treatment with a fixed-dose combina-
tion of sofosbuvir–velpatasvir once daily were 
superior to those among patients who received 
standard treatment with sofosbuvir–ribavirin. 
The rates of adverse events and laboratory ab-
normalities were lower among patients receiving 
sofosbuvir–velpatasvir than among those receiv-
ing sofosbuvir–ribavirin.
Although the current standard treatment of 
12 weeks of sofosbuvir plus ribavirin is effective 
in patients with HCV genotype 2, with rates of 
sustained virologic response of more than 90% 
in most subgroups, patients with cirrhosis and 
those who have not had a response to previous 
HCV treatment have an increased likelihood of 
HCV relapse. Furthermore, some patients are not 
eligible for sofosbuvir–ribavirin treatment be-
cause of contraindications to the use of ribavirin. 
None of the 134 patients with HCV genotype 2 
who received sofosbuvir–velpatasvir had virologic 
failure in a population that included patients 
with cirrhosis and previous treatment failure, 
and anemia was not observed. Also now reported 
in the Journal are the results of the ASTRAL-1 
trial,14 which assesses the efficacy of 12 weeks 
of sofosbuvir–velpatasvir in patients with HCV 
genotypes 1, 2, 4, 5, or 6, including patients 
with cirrhosis and those with previous treatment 
failure. Of the 104 patients in that study with 
HCV genotype 2, 100% had a sustained viro-
logic response. The rate of sustained virologic 
response among patients who received 12 weeks 
of sofosbuvir–ribavirin in our active-comparator 
group was 94%, which is similar to the rate of 
93% that was reported in a similar population 
receiving the same treatment in the phase 3 
VALENCE trial.15
The treatment of patients with HCV genotype 3 
has remained a clinical challenge in the era of 
direct-acting antiviral agents. Patients with HCV 
genotype 3, especially those who have not had a 
response to previous treatment and those with 
cirrhosis, have relatively poor rates of response 
to standard treatment with sofosbuvir–ribavirin. 
In the ALLY-3 phase 3 trial, among patients with 
HCV genotype 3 who received 12 weeks of sofos-
buvir with the NS5A inhibitor daclatasvir, a sus-
tained virologic response was reported in 90% 
of previously untreated patients and in 86% of 
previously treated patients. However, the response 
rate fell to 63% among patients with compen-
sated cirrhosis.16 The addition of peginterferon 
to sofosbuvir–ribavirin has been shown to im-
prove outcomes but at the expense of greater 
toxic effects and the exclusion of patients who 
have unacceptable side effects from interferon.17 
In this context, the finding that the rates of sus-
tained virologic response in every subgroup of 
patients with HCV genotype 3 were substantially 
higher among those who had received sofosbu-
vir–velpatasvir, including patients with cirrhosis 
and previous treatment failure, represents an 
improvement over standard treatment with 24 
weeks of sofosbuvir–ribavirin, with a shorter 
duration of treatment and fewer side effects ow-
ing to the removal of ribavirin from the regi-
men. The rates of response in the sofosbuvir–
ribavirin group in our study and in a similar 
population receiving the same regimen in the 
phase 3 VALENCE trial were 80% and 85%, re-
spectively.15
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Among patients with HCV genotype 2 who re-
ceived sofosbuvir–velpatasvir, the presence of base-
line NS5A or NS5B resistance-associated variants 
was not associated with virologic failure. However, 
among patients with HCV genotype 3, the rate 
of sustained virologic response was 88% among 
patients who had NS5A resistance-associated 
variants at baseline and 97% among those who 
did not, with the lowest rate (84%) observed 
among patients with the Y93H variant at base-
line. Further research is needed to evaluate poten-
tial strategies to increase the rate of sustained 
virologic response, such as prolongation of therapy 
or the addition of a third antiviral drug (e.g., riba-
virin or an active direct-acting antiviral agent with 
a different mechanism of action) in these patients.
In both the ASTRAL-2 and ASTRAL-3 trials, 
the generalizability of the results may be limited 
by the small number of black patients who were 
enrolled, which primarily was the result of the 
low prevalence of infection with HCV genotype 2 
or 3 among blacks in certain regions, including the 
United States. In addition, although patients with 
compensated cirrhosis were evaluated in these 
studies, patients with decompensated liver dis-
ease were excluded. However, in the ASTRAL-4 
trial,18 another phase 3 study now reported in 
the Journal, investigators evaluated the use of 
sofosbuvir–velpatasvir with or without ribavirin 
in patients with decompensated cirrhosis.
In conclusion, the results of the two trials 
reported here combined with the results of the 
ASTRAL-1 trial show that treatment with sofos-
buvir–velpatasvir for 12 weeks was highly effec-
tive regardless of HCV genotype.
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